Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200010/S026

Guardant360 CDx

Guardant Health, Inc. · Decision date Jan 15, 2026

FDA DECISIONP200010/S026

What did the FDA approve?

FDA records P200010/S026 as a supplement to PMA P200010, with the supplement type “Panel Track”. The recorded decision is approval, dated Jan 15, 2026.

FDA approval order statement

Guardant360 CDx is a qualitative next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of single nucleotide variants (SNVs), insertions and deletions (indels) in 55 genes, copy number amplifications (CNAs) in two (2) genes, and fusions in four (4) genes. Guardant360 CDx utilizes circulating cell-free DNA (cfDNA) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs). The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the therapies listed in Table 1 in accordance with the approved therapeutic product labeling.A negative result from a plasma specimen does not assure that the patients tumor is negative for genomic findings. Patients who are negative for the biomarkers listed in Table 1 should be reflexed to tissue biopsy testing for Table 1 biomarkers using an FDA-approved tumor tissue test, if feasible.*The efficacy of TAGRISSO (osimertinib) has not been established in the EGFR T790M plasma-positive, tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore, testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained.Additionally, the test is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for cancer patients with any solid malignant neoplasm. The test is for use with patients previously diagnosed with cancer and in conjunction with other laboratory and clinical findings.Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.Guardant360 CDx is a single-site assay performed at Guardant Health, Inc.
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Pathology
Decision date
Jan 15, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P200010/S026
Regulatory pathway
PMA supplement
Product code
PQP
Decision code
APPR
Decision date
Jan 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

For the original device and its historical approval scope, see PMA P200010. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200010/S026 received

    Application receipt date recorded by FDA.

  2. P200010/S026 · FDA decision

    Panel Track

Timeline entries are records held by MedtechLedger for P200010. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200010

Product / regulatory recordCompanyPathwayDecision dateSource
Guardant Health, Inc.PMA approvalAug 7, 2020FDA
Guardant360 CDxP200010/S021
Guardant Health, Inc.PMA supplementSep 25, 2025FDA
Guardant360 CDxP200010/S028
Guardant Health, Inc.PMA supplementDec 29, 2025FDA
Guardant360 CDxP200010/S025
Guardant Health, Inc.PMA supplementMay 1, 2026FDA
Guardant360 CDxP200010/S027
Guardant Health, Inc.PMA supplementJun 10, 2026FDA
Guardant360 CDxP200010/S031
Guardant Health, Inc.PMA supplementJul 6, 2026FDA
Guardant360 CDxP200010/S030
Guardant Health, Inc.PMA supplementJul 14, 2026FDA
Guardant360 CDxP200010/S032
Guardant Health, Inc.PMA supplementAug 7, 2026FDA
Guardant360 CDxP200010/S024
Guardant Health, Inc.PMA supplementSep 4, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Guardant Health, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
505 Penobscot Dr., Redwood City, CA, 94063

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records